title: The mechanisms by which antidepressants may reduce coronary heart disease risk.
abstract: BACKGROUND
  Depression is known to increase the risk for coronary heart disease (CHD) likely through various pathogenetic actions. Understanding the links between depression and CHD and the effects of mediating these links may prove beneficial in CHD prevention.
  
  
  METHODS
  An integrated model of CHD was used to elucidate pathogenetic pathways of importance between depression and CHD. Using biomarker relative risk data the pathogenetic effects are representable as measurable effects based on changes in biomarkers.
  
  
  RESULTS
  A 'connection graph' presents interactions by illustrating the relationship between depression and the biomarkers of CHD. The use of selective serotonin reuptake inhibitors (SSRIs) is postulated to have potential to decrease CHD risk. Comparing the 'connection graph' of SSRI's to that of depression elucidates the possible actions through which risk reduction may occur.
  
  
  CONCLUSIONS
  The CHD effects of depression appear to be driven by increased inflammation and altered metabolism. These effects might be mediated with the use of SSRI's.
authors.affiliation: CRCED Pretoria, North-West University, P.O. Box 11207, Silver Lakes, 0054, South Africa. mjmathews@rems2.com.
authors.forename: Marc J
authors.initials: MJ
authors.lastname: Mathews
authors.affiliation: CRCED Pretoria, North-West University, P.O. Box 11207, Silver Lakes, 0054, South Africa. ehmathews@researchtoolbox.com.
authors.forename: Edward H
authors.initials: EH
authors.lastname: Mathews
authors.affiliation: CRCED Pretoria, North-West University, P.O. Box 11207, Silver Lakes, 0054, South Africa. lliebenberg@researchtoolbox.com.
authors.forename: Leon
authors.initials: L
authors.lastname: Liebenberg
mesh_terms: D000928:Antidepressive Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000150:complications / Q000378:metabolism*; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000378:metabolism; D006943:Hyperglycemia / Q000150:complications / Q000378:metabolism; D006946:Hyperinsulinism / Q000150:complications / Q000378:metabolism; D006973:Hypertension / Q000150:complications / Q000378:metabolism; D007249:Inflammation / Q000150:complications / Q000378:metabolism; D008955:Models, Cardiovascular; D065840:Protective Factors; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D019851:Thrombophilia / Q000150:complications / Q000378:metabolism
chemical_list: D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors